Transcription suppression of SARI (suppressor of AP-1, regulated by IFN) by BCR-ABL in human leukemia cells (Q34213580)

31 July 2017

title

Transcription suppression of SARI (suppressor of AP-1, regulated by IFN) by BCR-ABL in human leukemia cells (English)

1 reference

31 July 2017

1 reference

Qing Huang

1

1 reference

31 July 2017

Yan Yang

series ordinal

2

1 reference

31 July 2017

Xiaoqing Li

series ordinal

3

1 reference

31 July 2017

Shiang Huang

series ordinal

4

1 reference

31 July 2017

publication date

3 September 2011

1 reference

31 July 2017

1 reference

31 July 2017

volume

32

1 reference

31 July 2017

issue

6

1 reference

31 July 2017

page(s)

1191-1197

1 reference

Molecular biology of bcr-abl1-positive chronic myeloid leukemia

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0222-1

Impact of BCR-ABL mutations on patients with chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0222-1

JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0222-1

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0222-1

Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0222-1

Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0222-1

Tumor suppressor gene inactivation in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0222-1

Tumor suppressor genes in myeloid differentiation and leukemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0222-1

A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0222-1

Cloning and characterization of SARI (suppressor of AP-1, regulated by IFN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0222-1

Targeting of integrin-linked kinase with a small interfering RNA suppresses progression of experimental proliferative vitreoretinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0222-1

SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0222-1

Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0222-1

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0222-1

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0222-1

Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0222-1

Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0222-1

AP-1: a double-edged sword in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0222-1

The molecular biology of chronic myeloid leukemia.

21 January 2018

1 reference

12 December 2020

In vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment

1 reference

12 December 2020

In vitro effect of STI571 on expression of c-kit in bone marrow cells from patients with acute non-lymphocytic leukemia

1 reference

12 December 2020

STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells.

1 reference

12 December 2020

Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses

1 reference

12 December 2020

The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation

1 reference

12 December 2020

BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia.

1 reference

12 December 2020

10.1007/S13277-011-0222-1

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1001282919

0 references

1 reference